RANVU DIN 02568950
Status: Approved
Holder: APOTEX INC
Health Canada record
| Active ingredient(s) | RANIBIZUMAB 10 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Intravitreal |
|---|
| Schedule | PRESCRIPTION; SCHEDULE D |
|---|
| Class | Human |
|---|
| ATC | S01LA04 RANIBIZUMAB |
|---|
| Original market date | |
|---|
| Current status date | 10-Jun-2026 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Apotex Inc — licence 100375, currently licensed, last inspection rating C (2026-09-21).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing RANIBIZUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02425629 | LUCENTIS | NOVARTIS PHARMACEUTICALS CANADA INC | Solution | RANIBIZUMAB 10 MG | Marketed |
| 02296810 | LUCENTIS | NOVARTIS PHARMACEUTICALS CANADA INC | Solution | RANIBIZUMAB 10 MG | Marketed |
| 02525852 | MELVIZO | SAMSUNG BIOEPIS CO., LTD | Solution | RANIBIZUMAB 10 MG | Marketed |
| 02542250 | RANOPTO | TEVA CANADA LIMITED | Solution | RANIBIZUMAB 10 MG | Marketed |
| 02568942 | RANVU | APOTEX INC | Solution | RANIBIZUMAB 10 MG | Approved |
| 02530589 | SUSVIMO | HOFFMANN-LA ROCHE LIMITED | Solution | RANIBIZUMAB 100 MG | Approved |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 37685 | 2026-06-10 | New Drug Submission (NDS) | |
Request a quote for RANVU
How to read a Canadian DIN record